December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. Through this agreement, Vetoquinol will develop and commercialize Klox’s fluorescent light energy (FLE) products in animal health.
At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.
Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners.
The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.
Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year. Changes in exchanges rates resulted in a positive currency impact of 1.4% only affecting the Americas region.
Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
In the first nine months of 2018, Vetoquinol recorded sales of €268.1 million, up 3.8% at constant exchange rates and 0.4% as reported.
Vetoquinol, a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms.
At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements.
VETOQUINOL PUBLISHES ITS HALF-YEARLY FINANCIAL REPORT RELATIVE TO FISCAL YEAR 2018
The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin.
The registration document of Vetoquinol relative to fiscal year 2017, including the annual financial report relative to fiscal year 2017, was filed with the Autorité des marchés financiers (“the AMF”) on April 23, 2018.
Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee.
At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements.
The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%.
Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT.
Vetoquinol has been listed on the Euronext Paris stock market since November 16th.
Composition of the bodies of Corporate Management and Governance
Financial information and key figures: annual, half-year and by sector key figures